VAP combination

1.	Peretti, Diego: 1 article (06/2008)
2.	Dahan, Nili: 1 article (06/2008)
3.	Ben Halevy, Daniel: 1 article (06/2008)
4.	Lev, Sima: 1 article (06/2008)
5.	Haasdijk, Elize: 1 article (09/2007)
6.	Demmers, Jeroen: 1 article (09/2007)
7.	Akhmanova, Anna: 1 article (09/2007)
8.	Ahmed, Suaad: 1 article (09/2007)
9.	Steinmetz, Michel O: 1 article (09/2007)
10.	Teuling, Eva: 1 article (09/2007)

Related Diseases

1.	Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated) 02/01/2004 - "The best route of nutrition in the acute phase, actual efficacy of immune system-enhancing diets, and the prevention of bacterial translocation (BT) and Ventilator-associated pneumonia (VAP) should be resolved. " 03/29/2008 - "Seven randomized clinical trials have been published that showed a significant reduction in ventilator associated pneumonia (VAP) incidence, but not on survival. " 08/01/2008 - "BACKGROUND: Accurate diagnosis and appropriate treatment of ventilator associated pneumonia (VAP) is crucial for good outcomes. " 04/01/2006 - "Our goal was to describe the successful application of PBL to patient care improvement with development of an algorithm for the empiric therapy of ventilator-associated pneumonia (VAP). " 09/01/2007 - "BACKGROUND: Several interventions have been shown to be effective in reducing the incidence of ventilator-associated pneumonia (VAP), but their implementation in clinical practice has not gained widespread acceptance. " Order ALL the reference details at left...
2.	Pneumonia (Pneumonitis) 07/01/2005 - "Pneumonia scores, chest radiography, and bronchoscopy are all employed, but there is no gold standard test for the diagnosis of VAP. " 01/01/2005 - "CONCLUSION: We conclude that in our study, the closed-tracheal suction system did not reduce VAP incidence, even for exogenous pneumonia." 07/01/1998 - "In this model where many of the confounding factors often present in human studies were absent, we found that (1) although the local bacterial burden tended to correlate with the presence and the severity of histologic lesions, no definite bacteriologic cutoff could differentiate the histologic presence or absence of pneumonia; (2) histologic lesions of pneumonia and parenchymal bacterial burden were unevenly distributed through the lungs; (3) this heterogeneity in bacterial distribution also held true for single bacterial species; (4) using discriminative values of >= 10(3) cfu/ml, >= 10(4) cfu/ml, and >= 10(5) cfu/ml to define positive PSB, BAL, and EA cultures, respectively, these techniques identified the histologic presence of pneumonia with a sensitivity of 69%, 78%, and 100%, respectively; (5) the specificity of these techniques in recognizing VAP was less than 50%; (6) with these discriminative values, less than 50% of PSB and BAL specimens correctly identified the causative organisms, whereas 94% of EA specimens correctly established the microbiologic diagnosis of pneumonia. " 07/01/2009 - "Median k was 24.4 (9.7-40.2) in VAP group and 24.6 (13.1-57.8) in patients without pneumonia (NS). " 07/01/2009 - "The parameters including ventilation and oxygenation, ventilation duration, ventilation-associated pneumonia (VAP), duration of respiratory intensive care unit (RICU) stay were serially determined. " Order ALL the reference details at left...
3.	Neoplasms (Cancer) 11/01/2007 - "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that VAP implantation into the femoral vein provides an acceptable means of chronic venous access in dogs and cats undergoing cancer treatment." 02/15/2002 - "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that samples obtained from VAP are suitable for routine hematologic monitoring of feline cancer patients. " 02/15/2002 - "If proper techniques are used, VAP may be used for administration of chemotherapy as well as for blood collection in cats undergoing cancer treatment." 10/01/1984 - "The activity of VAP chemotherapy is comparable with the most effective multidrug regimens of the present time in patients with advanced non-small cell tumors. " 06/01/1999 - "The aim of the present study was to evaluate the interest of the PTC to diagnose VAP in ventilated cancer patients. " Order ALL the reference details at left...
4.	Infection 06/15/2001 - "Of the 16 patients who were treated with the ALT, 5 (31%) were cured, as determined by negative cultures of blood and of samples from the catheter; 2 (12.5%) were cured but had recurrent infection with another microorganism; and 9 (56%) had persistent positive cultures of blood and of samples from the tip, reservoir, or both of the VAP. " 09/01/2008 - "DESIGN: This was a descriptive study, using data from a national collaborative focused on reducing VAP and catheter-related bloodstream infections. " 07/01/2008 - "Microbiologic studies have shown that the organisms which cause infections in HAP and VAP differ from CAP in epidemiology and resistance patterns. " 04/01/2006 - "The study also evaluates the clinical diagnosis of VAP based on the inclusion of Gram stain results of BBS/ETA samples into modified clinical pulmonary infection score (CPIS). " 03/01/2006 - "MEASUREMENTS AND MAIN RESULTS: Study end points were VAP diagnosed on the basis of Clinical Pulmonary Infection Score (CPIS) (), HME resistance after 24 hrs of use, endotracheal tube resistance, and HME use per patient. " Order ALL the reference details at left...
5.	Critical Illness (Critically Ill) 01/01/2007 - "We undertook a randomized, prospective trial of critically ill patents with (MDR) Acinetobacter baumannii VAP. " 05/01/2009 - "Because of its acknowledged benefits and lack of demonstrable risks, de-escalation therapy should be used whenever possible in critically ill patients with VAP." 05/01/2009 - "CONCLUSION: De-escalation therapy did not lead to RP or increased mortality in critically ill surgical patients with VAP. " 05/01/2009 - "CONCLUSIONS: Enteral administration of Synbiotic 2000 FORTE has no statistically significant impact on the incidence of VAP in critically ill patients." 09/01/2008 - "METHOD: We examine the need for an endotracheal tube (ETT) specifically designed for the critically-ill patient, the development of the LoTrach system from conception to production, and the role of the various components of the system in preventing VAP. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ceftazidime (Fortum)
2.	Colistin (Coly-Mycin)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Doxorubicin (Adriamycin)
5.	Vincristine (Oncovin)
6.	meropenem (Merrem)
7.	Vancomycin
8.	Piperacillin
9.	tigecycline (Tygacil)
10.	linezolid (Zyvox)

Related Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation)
2.	Intensive Care (Surgical Intensive Care)
3.	Chemoprevention
4.	Mechanical Ventilators (Ventilator)
5.	Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Ventilator-Associated Pneumonia

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 39 Outcomes
Top 131 Key Drugs and Biologics
Top 46 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>